Laura Joszt, MA

The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical trials.

A decision-analytic model could save more than $7 million in overall ineffective health care costs per 1000 patients by predicting which patients with rheumatoid arthritis (RA) will have an inadequate response to anti–tumor necrosis factor therapies.

Patients with spinal muscular atrophy (SMA) incur significant health care resource utilization and cost burden, particularly those with infantile-onset SMA.

The Mediterranean diet, which is known to have health benefits, may help prevent rheumatoid arthritis (RA) in current or previous smokers, according to new research published in Arthritis & Rheumatology.

There are now multiple therapeutic options available for spinal muscular atrophy (SMA), a disease once considered incurable; however, there remains a need for additional treatments and better ways to predict treatment response.

Findings from a new study in JAMA do not support the use of vitamin D3 supplementation to prevent severe asthma exacerbations in children with persistent asthma.

Comorbidities can have an impact on the main disease domains for patients with psoriatic arthritis. For each additional comorbidity a patient has, their disease activity score increases.

It may be possible to modify some lifestyle and environmental factors to reduce the risk of patients transitioning from psoriasis to psoriatic arthritis.

Reproductive carrier screening can identify conditions like spinal muscular atrophy, but this testing is often not done at all or not done before a woman gets pregnant, according to a new study.

Despite progress from disease-modifying antirheumatic drugs, there is still a far greater long-term risk of undergoing total knee and hip arthroplasties in patients with rheumatoid arthritis.

In addition to high health care and societal costs, spinal muscular atrophy (SMA) is associated with a deterioration in the health-related quality of life of both patients and their caregivers in 3 European countries.

Cardiometabolic comorbidities are a considerable burden in patients with psoriatic arthritis, and patients who had a higher number of cardiovascular (CV) risk factors had greater disease activity, according to a study in Medicina.

Most people with systemic lupus erythematosus and inflammatory arthritis, who use medications that make them immunosuppressed, are not necessarily at greater risk of hospitalization from coronavirus disease 2019 (COVID-19), according to 2 studies.

The burden of disease in patients with axial psoriatic arthritis (PsA) can differ significantly between genders, according to a new study published in Modern Rheumatology.

The FDA approved the drug on August 7, and on August 17, the European Medicines Agency (EMA) accepted the marketing authorization application for the spinal muscular atrophy (SMA) treatment.

In a Complete Response Letter, FDA is requesting additional data from Gilead Sciences for its investigational treatment for moderately to severely active rheumatoid arthritis (RA).

Sanofi and Johnson & Johnson are making moves to expand their autoimmune portfolios with recently announced acquisitions.

Secukinumab 150 mg improves signs and symptoms of patients with nonradiographic axial spondyloarthritis, according to results of the PREVENT trial published in Arthritis & Rheumatology.

A new study of patients with rheumatoid arthritis (RA) in Korea has shown that only about half of patients with RA who attained clinical remission were also in imaging remission.

Patients with connective tissue diseases are at greater risk for severe coronavirus disease 2019 (COVID-19) than patients with chronic inflammatory arthritis.

The risk of orthopedic surgery has declined for patients with rheumatoid arthritis (RA) over the course of decades, but the same trend has not occurred for patients with psoriatic arthritis.

Most studies have evaluated PsA-associated fatigue in western populations. A new study has highlighted that PsA-associated fatigue is also prevalent in an Asian population and correlates with disease activity, impact, and chronicity.

A new study in PLOS ONE has highlighted the broad impact fatigue can have on patients with rheumatoid arthritis (RA), psoriatic arthritis, and axial spondyloarthritis.

In the primary analysis of a phase 3 study, ruxolitinib reduced spleen length and symptoms in patients with myelofibrosis, according to results published in British Journal of Haemotology.

Just like in clinical trials, a real-world analysis of patients with psoriatic arthritis who were treated with secukinumab achieved minimal disease activity, as well as other improvements.

Despite concerns, legislation to cap out-of-pocket payments for specialty drugs has not been shown to shift costs to health plans, thereby increasing insurance premiums, according to a study published in New England Journal of Medicine.

The coronavirus disease 2019 (COVID-19) vaccines that are leading the pack are utilizing a new vaccine technology that has never been approved for human use by the FDA. As a result, there are a lot of unknowns.

Patients with rheumatoid arthritis (RA) have a higher risk of cardiovascular disease (CVD), because inflammation plays a pivotal role in the development of CVD. However, there is a need for greater improvement of CVD risk prevention.

During the coronavirus disease 2019 (COVID-19) pandemic, clinics have closed to varying degrees. As clinics look to reopen or welcome back patients after a COVID-19 infection, the American College of Rheumatology (ACR) has released advice on strategies for reopening practices as the pandemic continues.

Patients with myeloproliferative neoplasms (MPNs) have high disease burden, and management of their disease can vary widely to include watchful waiting, phlebotomy, or drug therapy.